The Full Wiki

Nizatidine: Wikis

  

Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.

Encyclopedia

From Wikipedia, the free encyclopedia

Nizatidine
Systematic (IUPAC) name
N-(2-[(2-[(dimethylamino)methyl]thiazol-4-yl)methylthio]ethyl)- N-methyl-2-nitroethene-1,1-diamine
Identifiers
CAS number 76963-41-2
ATC code A02BA04
PubChem 3033637
DrugBank APRD00706
Chemical data
Formula C 12H21N5O2S2  
Mol. mass 331.46 g/mol
Pharmacokinetic data
Bioavailability >70%
Protein binding 35%
Metabolism Hepatic
Half life 1-2 hours
Excretion Renal
Therapeutic considerations
Licence data

US FDA:link

Pregnancy cat. B3(AU)
Legal status Prescription Only (S4) (AU) POM (UK) OTC (US)
Routes Oral
 Yes check.svgY(what is this?)  (verify)

Nizatidine is a histamine H2-receptor antagonist that inhibits stomach acid production, and commonly used in the treatment of peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD). It was developed by Eli Lilly and is marketed under the trade names Tazac and Axid.

Contents

Clinical use

Certain preparations of nizatidine are now available over the counter in various countries including the United States. Nizatadine has been used experimentally to control weight gain associated with some antipsychotic medication. [1]

History and development

Nizatidine was developed by Eli Lilly, and was first marketed in 1987. It is considered to be equipotent with ranitidine and differs by the substitution of a thiazole-ring in place of the furan-ring in ranitidine. In September 2000 Eli Lilly announced that they will sell the sales and marketing rights for Axid, to Reliant Pharmaceuticals. [2] Subsequently, Reliant developed the oral solution of Axid and got approval by the U.S. Food and Drug Administration (FDA) in May 2004 and started marketing it. [3] However, a year later they sold rights of the Axid Oral Solution (including the issued patent US6,930,119 protecting the product) to Braintree Laboratories.[4]

Nizatidine proved to be the last new histamine H2-receptor antagonists introduced prior to the advent of proton pump inhibitors.

References

  1. ^ Atmaca M, Kuloglu M, Tezcan E, Ustundag B, Kilic N (January 2004). "Nizatidine for the treatment of patients with quetiapine-induced weight gain". Hum Psychopharmacol 19 (1): 37–40. doi:10.1002/hup.477. PMID 14716710.  
  2. ^ Eli Lilly and Company and Reliant Pharmaceuticals Announce
  3. ^ Reliant Pharmaceuticals : Press Releases
  4. ^ Reliant Pharmaceuticals : Press Releases

External links








Got something to say? Make a comment.
Your name
Your email address
Message